Copyright Reports & Markets. All rights reserved.

Global and China Pulmonary Arterial Hypertension (PAH) Drugs Market Insights, Forecast to 2026

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Pulmonary Arterial Hypertension (PAH) Drugs Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type
    • 1.4.2 Inhalation
    • 1.4.3 Injectables
    • 1.4.4 Oral Administration
  • 1.5 Market by Application
    • 1.5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application
    • 1.5.2 Hospitals
    • 1.5.3 Clinics
    • 1.5.4 Other
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, Estimates and Forecasts
    • 2.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue 2015-2026
    • 2.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2015-2026
  • 2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.3 Pulmonary Arterial Hypertension (PAH) Drugs Historical Market Size by Region (2015-2020)
    • 2.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
  • 2.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Projections by Region (2021-2026)
    • 2.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Region (2021-2026)
    • 2.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Region (2021-2026)

3 Global Pulmonary Arterial Hypertension (PAH) Drugs Competitor Landscape by Players

  • 3.1 Global Top Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers
    • 3.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers (2015-2020)
    • 3.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers by Revenue
    • 3.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2015-2020)
    • 3.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2019
    • 3.2.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturers
  • 3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution, Product Types
    • 3.4.1 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
    • 3.4.3 Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type (2015-2020)
    • 4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020)
    • 4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2015-2020)
    • 4.1.3 Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Type (2021-2026)
    • 4.2.3 Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application (2015-2020)
    • 5.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020)
    • 5.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2015-2020)
    • 5.1.3 Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2015-2020)
  • 5.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2021-2026)

6 China by Players, Type and Application

  • 6.1 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2015-2026
    • 6.1.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY Growth 2015-2026
    • 6.1.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY Growth 2015-2026
    • 6.1.3 China Pulmonary Arterial Hypertension (PAH) Drugs Market Share in Global Market 2015-2026
  • 6.2 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Players (International and Local Players)
    • 6.2.1 China Top Pulmonary Arterial Hypertension (PAH) Drugs Players by Sales (2015-2020)
    • 6.2.2 China Top Pulmonary Arterial Hypertension (PAH) Drugs Players by Revenue (2015-2020)
  • 6.3 China Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Review by Type (2015-2020)
    • 6.3.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
    • 6.3.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2015-2020)
    • 6.3.3 China Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2015-2020)
  • 6.4 China Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Forecasts by Type (2021-2026)
    • 6.4.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2021-2026)
    • 6.4.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Type (2021-2026)
    • 6.4.3 China Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Type (2021-2026)
  • 6.5 China Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Review by Application (2015-2020)
    • 6.5.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
    • 6.5.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2015-2020)
    • 6.5.3 China Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2015-2020)
  • 6.6 China Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Forecasts by Application (2021-2026)
    • 6.6.1 China Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2021-2026)
    • 6.6.2 China Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Application (2021-2026)
    • 6.6.3 China Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2021-2026)

7 North America

  • 7.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2015-2026
  • 7.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
    • 7.2.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2015-2020)
    • 7.2.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2015-2020)
    • 7.2.3 U.S.
    • 7.2.4 Canada

8 Europe

  • 8.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2015-2026
  • 8.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
    • 8.2.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
    • 8.2.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
    • 8.2.3 Germany
    • 8.2.4 France
    • 8.2.5 U.K.
    • 8.2.6 Italy
    • 8.2.7 Russia

9 Asia Pacific

  • 9.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2015-2026
  • 9.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
    • 9.2.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2015-2020)
    • 9.2.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region
    • 9.2.3 China
    • 9.2.4 Japan
    • 9.2.5 South Korea
    • 9.2.6 India
    • 9.2.7 Australia
    • 9.2.8 Taiwan
    • 9.2.9 Indonesia
    • 9.2.10 Thailand
    • 9.2.11 Malaysia
    • 9.2.12 Philippines
    • 9.2.13 Vietnam

10 Latin America

  • 10.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2015-2026
  • 10.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
    • 10.2.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
    • 10.2.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
    • 10.2.3 Mexico
    • 10.2.4 Brazil
    • 10.2.5 Argentina

11 Middle East and Africa

  • 11.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size YoY Growth 2015-2026
  • 11.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Country
    • 11.2.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
    • 11.2.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
    • 11.2.3 Turkey
    • 11.2.4 Saudi Arabia
    • 11.2.5 U.A.E

12 Company Profiles

  • 12.1 Pfizer
    • 12.1.1 Pfizer Corporation Information
    • 12.1.2 Pfizer Description and Business Overview
    • 12.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 12.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.1.5 Pfizer Recent Development
  • 12.2 Glaxosmithkline
    • 12.2.1 Glaxosmithkline Corporation Information
    • 12.2.2 Glaxosmithkline Description and Business Overview
    • 12.2.3 Glaxosmithkline Sales, Revenue and Gross Margin (2015-2020)
    • 12.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.2.5 Glaxosmithkline Recent Development
  • 12.3 Novartis
    • 12.3.1 Novartis Corporation Information
    • 12.3.2 Novartis Description and Business Overview
    • 12.3.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
    • 12.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.3.5 Novartis Recent Development
  • 12.4 United Therapeutics
    • 12.4.1 United Therapeutics Corporation Information
    • 12.4.2 United Therapeutics Description and Business Overview
    • 12.4.3 United Therapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 12.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.4.5 United Therapeutics Recent Development
  • 12.5 AstraZeneca
    • 12.5.1 AstraZeneca Corporation Information
    • 12.5.2 AstraZeneca Description and Business Overview
    • 12.5.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
    • 12.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.5.5 AstraZeneca Recent Development
  • 12.6 Merck
    • 12.6.1 Merck Corporation Information
    • 12.6.2 Merck Description and Business Overview
    • 12.6.3 Merck Sales, Revenue and Gross Margin (2015-2020)
    • 12.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.6.5 Merck Recent Development
  • 12.7 Bayer Healthcare
    • 12.7.1 Bayer Healthcare Corporation Information
    • 12.7.2 Bayer Healthcare Description and Business Overview
    • 12.7.3 Bayer Healthcare Sales, Revenue and Gross Margin (2015-2020)
    • 12.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.7.5 Bayer Healthcare Recent Development
  • 12.8 Actelion Pharmaceuticals
    • 12.8.1 Actelion Pharmaceuticals Corporation Information
    • 12.8.2 Actelion Pharmaceuticals Description and Business Overview
    • 12.8.3 Actelion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 12.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.8.5 Actelion Pharmaceuticals Recent Development
  • 12.9 Daiichi Sankyo
    • 12.9.1 Daiichi Sankyo Corporation Information
    • 12.9.2 Daiichi Sankyo Description and Business Overview
    • 12.9.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
    • 12.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.9.5 Daiichi Sankyo Recent Development
  • 12.10 Northern Therapeutics
    • 12.10.1 Northern Therapeutics Corporation Information
    • 12.10.2 Northern Therapeutics Description and Business Overview
    • 12.10.3 Northern Therapeutics Sales, Revenue and Gross Margin (2015-2020)
    • 12.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.10.5 Northern Therapeutics Recent Development
  • 12.11 Pfizer
    • 12.11.1 Pfizer Corporation Information
    • 12.11.2 Pfizer Description and Business Overview
    • 12.11.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
    • 12.11.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
    • 12.11.5 Pfizer Recent Development
  • 12.12 Arena Pharmaceuticals
    • 12.12.1 Arena Pharmaceuticals Corporation Information
    • 12.12.2 Arena Pharmaceuticals Description and Business Overview
    • 12.12.3 Arena Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 12.12.4 Arena Pharmaceuticals Products Offered
    • 12.12.5 Arena Pharmaceuticals Recent Development
  • 12.13 Berlin Cures
    • 12.13.1 Berlin Cures Corporation Information
    • 12.13.2 Berlin Cures Description and Business Overview
    • 12.13.3 Berlin Cures Sales, Revenue and Gross Margin (2015-2020)
    • 12.13.4 Berlin Cures Products Offered
    • 12.13.5 Berlin Cures Recent Development
  • 12.14 Eiger BioPharmaceuticals
    • 12.14.1 Eiger BioPharmaceuticals Corporation Information
    • 12.14.2 Eiger BioPharmaceuticals Description and Business Overview
    • 12.14.3 Eiger BioPharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 12.14.4 Eiger BioPharmaceuticals Products Offered
    • 12.14.5 Eiger BioPharmaceuticals Recent Development
  • 12.15 Reata Pharmaceuticals
    • 12.15.1 Reata Pharmaceuticals Corporation Information
    • 12.15.2 Reata Pharmaceuticals Description and Business Overview
    • 12.15.3 Reata Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
    • 12.15.4 Reata Pharmaceuticals Products Offered
    • 12.15.5 Reata Pharmaceuticals Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Pulmonary Arterial Hypertension (PAH) Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Pulmonary Arterial Hypertension (PAH) Drugs Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Pulmonary Arterial Hypertension (PAH) Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Segment by Type, the Pulmonary Arterial Hypertension (PAH) Drugs market is segmented into
    Inhalation
    Injectables
    Oral Administration

    Segment by Application, the Pulmonary Arterial Hypertension (PAH) Drugs market is segmented into
    Hospitals
    Clinics
    Other

    Regional and Country-level Analysis
    The Pulmonary Arterial Hypertension (PAH) Drugs market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Pulmonary Arterial Hypertension (PAH) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

    Competitive Landscape and Pulmonary Arterial Hypertension (PAH) Drugs Market Share Analysis
    Pulmonary Arterial Hypertension (PAH) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Pulmonary Arterial Hypertension (PAH) Drugs business, the date to enter into the Pulmonary Arterial Hypertension (PAH) Drugs market, Pulmonary Arterial Hypertension (PAH) Drugs product introduction, recent developments, etc.
    The major vendors covered:
    Pfizer
    Glaxosmithkline
    Novartis
    United Therapeutics
    AstraZeneca
    Merck
    Bayer Healthcare
    Actelion Pharmaceuticals
    Daiichi Sankyo
    Northern Therapeutics
    Aires Pharmaceuticals
    Arena Pharmaceuticals
    Berlin Cures
    Eiger BioPharmaceuticals
    Reata Pharmaceuticals

    Buy now